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PROGNOSTIC SYSTEM FOR CHOLANGIOCARCINOMA 
Proposal of prognostic nomogram for perihilar cholangiocarcinoma after surgical resection and 
comparison with pre-existing staging systems 
 
 
ABSTRACT 
 
Introduzione 
Il colangiocarcinoma perilare (PCC) è un tumore primitivo della via biliare con progressivo incremento di 
incidenza negli ultimi anni e la sua classificazione, gestione clinica e chirurgica si sta modificando negli anni 
recenti. Il PCC ha una prognosi infausta ma la resezione radicale chirurgica può prolungare la 
sopravvivenza. 
Sono disponibili diverse classificazioni prognostiche e sistemi stadiativi ma nonostante ciò non esiste 
accordo diffuso sul loro significato prognostico.  
Obiettivo dello studio è di creare un nomogramma con funzione di valutare la prognosi per i pazienti con 
PCC sottoposti ad intervento chirurgico con intento radicale.  
 
Materiali e Metodi 
Un database prospettico di pazienti sottoposti ad intervento chirurgico per colangiocarcinoma in uno stesso 
reparto di chirurgia è stato la base per valutare le caratteristiche cliniche e patologiche dei pazienti con PCC 
sottoposti ad intervento chirurgico con intento radicale. Dalle variabili risultate significative all’analisi 
multivariata è stato creato un modello prognostico per valutare il rischio di mortalità a 3 anni dall’intervento 
chirurgico. Un nomogramma è stato quindi creato dal modello prognostico. Il nomogramma è stato validato 
internamente. La capacità di predire la sopravvivenza dopo intervento chirurgico per pazienti con PCC è 
stata confrontata tra altri quattro sistemi stadiativi o prognostici preesistenti e il tra il nostro nuovo modello 
prognostico.  
 
Risultati 
Da un database di 207 pazienti con colangiocarcinoma, 145 sono stati sottoposti ad intervento chirurgi con 
intento radicale tra il Settembre 1990 e il Settembre 2012; 75 sono stati classificati come PCC. Sei pazienti 
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sono stati esclusi dall’analisi perché deceduti nel periodo postoperatorio; 69 pazienti sono stati inclusi 
nell’analisi dello studio.  
Fattori prognostici per la sopravvivenza all’analisi multivariata sono risultati: CA 19.9 preoperatorio 
>500U/mL, numero di linfonodi prelevati, numero di linfonodi risultati positivi, resezione del caudato, 
resezione e ricostruzione portale. Dalle variabili significative all’analisi multivariata è stato creato un sistema 
prognostico, che è riuscito a distinguere i pazienti operati in tre gruppi a seconda del rischio di morire entro 3 
anni dall’intervento: basso (<50%), medio (50-75%) o alto (>75%) rischio. Dal sistema prognostico è stato 
ideato un nomogramma. La curva di calibrazione ha mostrato una buona concordanza tra la sopravvivenza 
prevista dal nomogramma e la sopravvivenza attesa. Il nostro modello prognostico è stato confrontato con 
altri sistemi stadiativi pre-esistenti: AJCC/UICC TNM, classificazione di MSKCC, sistema stadiativo JSBS e 
score prognostico di Kaiser dimostrando una migliore capacità di predire la sopravvivenza (AIC 268.9). 
 
Conclusione 
Il nostro nomogramma prognostico ha dimostrato di avere maggiore capacità di predire la sopravvivenza per 
i pazienti con PCC sottoposti ad intervento chirurgico.  
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Introduction 
Perihilar cholangiocarcinoma (PCC) is primary biliary malignancy increasing worldwide and its classification 
and management is evolving progressively. Perihilar cholangiocarcinoma has poor prognosis however 
surgical resection can prolong survival. Prognostic classification and scoring systems are available but there 
is not general agreement about their prognostic significance.  
Aim of this study was to create an effective prognostic nomogram for patients submitted to surgical resection 
for perihilar cholangiocarcinoma.  
 
Material and Methods 
Creation of nomogram was based on consecutive series of 69 patients submitted to surgical resection for 
perihilar cholangiocarcinoma between 1990 and 2012. Clinical and pathological variables were evaluated. 
Prognostic model for risk to die within 3 years after surgical resection was created according to variables 
selected at multivariate analysis. Nomogram was created by prognostic model. Internal validation of 
nomogram was performed. Predictive accuracy and discriminative capability of our prognostic model was 
compared with other four prognostic systems for PCC.  
 
Results 
From a database of 207 patients with cholangiocarcinoma, 145 were submitted to surgical resection with 
curative intent between September 1990 and September 2012; 75 were classified as PCC. Six patients were 
excluded from analysis due to perioperative mortality, thus 69 patients were included in study analysis. 
Independent significant prognostic factor for survival at multivariate analysis were increased CA 19.9, 
number of lymph node harvested, number of positive lymph node, caudate lobe resection and portal vein 
resection; all these variables were selected for prognostic model. Three group of patients according to low 
(<50%), medium (50-75%) or high (>75%) risk to die within 3 year were identified by nomogram. Calibration 
curve for probability of survival showed good agreement between prediction of nomogram and actual 
observation. Our prognostic model resulted more accurate in predict survival compared to AJCC/UICC TNM 
staging system, MSKCC classification, JSBS staging system and Kaiser prognostic scoring system (AIC 
268.9). 
 
Conclusion 
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Our prognostic nomogram resulted to be more accurate than previous staging system in predict survival for 
patients with perihilar cholangiocarcinoma submitted to surgical resection. 
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INTRODUCTION 
 
Cholangiocarcinoma is malignant transformation of bile duct epithelium; it represents proximally 10% of all 
primary hepatobiliary cancer 1, 2 . This tumor is the second most frequent primary liver tumor and its 
incidence is increasing in Western countries 3.    
Cholangiocarcinoma is classified as intrahepatic (ICC), perihilar (PCC) and distal type, according to its origin 
from proximal intrahepatic bile ducts (ICC), from the epithelium of the right or left hepatic ducts at biliary 
confluence (PCC) or from distal part of common bile duct 1, 4.  
Perihilar cholangiocarcinoma, also called Klatskin tumor 5, represent approximately two third of all cases of 
bile ducts tumors 4 . It was defined as tumor involving biliary confluence, however there are still some difficult 
in preoperative definition and proper histological classification 6 7.  
Different clinicopathological factors have been previously evaluated and related to survival: radical resection, 
vascular invasion, perineural invasion, tumor size, multifocality, lymph node metastasis, tumor stage, tumor 
grading and positive resection margins 8-10. 
Surgical radical resection (R0) and transplantation in selected cases are still the only therapeutic option to 
achieve longer survival 11-13 , however prognosis is dismal and rarely 5 years survival exceed 30% 14 .  
Staging systems give information about prognosis, stratification of patients according to tumor stage, guide 
for different type of therapy and allowed to compare different treatments among different institutions over the 
time 15. For these reasons, as for others tumors, also for perihilar cholangiocarcinoma were created different 
staging systems. 
 
Staging Systems 
Different staging systems are available to classify perihilar cholangiocarcinoma: Bismuth-Corlette 
classification 16, the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control 
(UICC) TNM classification 17, Memorial Sloan-Kettering Cancer Center (MSKCC) classification 18, Japanese 
Society of Biliary Surgery (JSBS) staging system 19, DeOliveira’s staging system 20 and Kaiser’s Prognostic 
Scoring System 21. 
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Bismuth-Corlette Classification.  
Bismuth-Corlette classification was introduced in 1975 and modified in 1992 16, 22; this classification is 
focused exclusively on the level and extension of the tumor invasion along the biliary tree (Fig. 1). Tumor is 
classified as type I (the tumor involves only the common hepatic duct below the confluence of the left and 
right hepatic ducts), type II (the tumor involves the hepatic bile duct confluence but there without invasion 
above the confluence), type III (the tumor involves the biliary confluence and is extent along right (type IIIa) 
or left (type IIIb) hepatic duct), or type IV (the tumor involves both the right and left hepatic ducts and the 
confluence reaching the secondary intrahepatic biliary system or involves multiple discontinuous sites in the 
right and left ducts). The Bismuth-Corlette classification was primarily conceived to serve as a guide for 
surgical strategy (e.g., types I and II indicate local resection, type III indicates associated liver resection, and 
type IV indicates unresectability), however recent practice in many specialized centres no longer follows the 
original concept 7, 20. This system fails to provide other key information such as vascular encasement, lymph 
node involvement, distant metastases and atrophy of a part of the liver. Thus, it logically does not correlate 
with patient survival, however in some papers it has be valuated as prognostic factor for survival  
 
Figure 1: Bismuth-Corlette Calssification 16. 
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TNM Staging System according to UICC/AJCC.  
This classification is based on the pathological findings of tumor extension, lymph node involvement and 
presence of metastases (Figure 2) 17. In 2010 the 7th edition of AJCC/UICC finally included TNM 
classification for perihilar cholangiocarcinoma, previously incorporated in extrahepatic bile ducts 
classification. This classification is a pathological classification and available only after surgical resection. 
This has little applicability because of low feasibility of surgical operation in this type of patient 7, 23 . This fails 
to indicate local resectability of the tumor and to distinguish between the various surgical options. Its 
usefulness in the preoperative setting is thus limited. In literature were validated the different edition of TNM 
stage also evaluating capability to differentiate prognosis of patients according to different stages 24, 25, 
however other studies did not reached comparable results 26, 27 . In majority of studies different classes are 
combined to reach a significant different survival amongst patients. For this reason, this classification has 
some limitations as prognostic value.  
 
Figure 2: TNM UICC/AJCC Staging System 17. 
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Memorial Sloan-Kettering Cancer Center (MSKCC) Classification.  
Group from MSKCC proposed a staging system that classifies PCC according to three factors related to the 
local extension of the tumor, the location of bile duct involvement and the presence of portal vein invasion 
and hepatic lobar atrophy (Figure 3) 18 . This classification was tested in a series of 225 patients from that 
institution and showed an accuracy of 86% in the preoperative staging of the local extent of the disease. This 
staging system attempted to predict resectability, however, there are some limitations: the system does not 
evaluate the presence of lymph node or distant metastases or the involvement of the artery, the size of the 
remnant liver is not specified and it was designed exclusively on the basis of the criteria of resectability from 
a single institution. The concept of resectability is evolving because of the recent developments in 
aggressive liver surgery with vascular resection and reconstruction and because of new advances in liver 
transplantation, and for this reason this system have some limitation in applicability. Moreover, also as 
prognostic factor this classification have some limitation; Zervos et al. did not confirmed the correlation 
between classification and long-term results 28. 
 
 
Figure 3: MSKCC Classification. Adapted form Jarnagin et al (2001) 18. 
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Staging System according to Japanese Society of Biliary Surgery (JSBS) 
Classification of hilar neoplasm formulated by JSBS was published in 2004 (Figure 5) 29. As TNM of 
UICC/AJCC, this classification is based on pathological findings. It analyzes tumor extension, lymph node 
involvement and distal metastases. Patients are classified in five stages: I, II, III, IVA, IVB.  
Also this classification have some limitations: useless preoperatively and to define resectability, perihilar 
cholangiocarcinoma classified along with others extrahepatic tumor of biliary tract, complexity of 
classification of tumor extension due to inclusion of five parameters (serosa, hepatic parenchyma, pancreas, 
portal vein and hepatic artery infiltration), classification different from TNM UICC/AJCC regarding lymph 
node staging and metastases. Thus, because of complexity of this precise staging system it was not diffused 
internationally.   
 
 
Figure 5: Japanese Society of Biliary Surgery staging system 29. 
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DeOliveira’s New Staging System for Perihilar Cholangiocarcinoma 
Recently was proposed a new classification of perihilar cholangiocarcinoma (Figure 6) 20. This classification 
give more information about vascular infiltration and remnant liver volume comparing to previous Staging 
System; this stage system incorporate Bismuth-Corlette classification and TNM staging 7th edition for 
perihilar cholangiocarcinoma associated to description of vascular invasion. Aims of this new more precise 
staging system were to get more radiological and pathological information and to create an international 
registry. However, there were some limits in this new staging system of perihilar cholangiocarcinoma: first of 
all this staging is descriptive and did not have availability as prognostic factor, definition of vascular 
infiltration is precise however non-realistic because vascular invasion is classified like Bismuth-Corlette 
classifies biliary infiltration and definition of perihilar cholangiocarcinoma was not assessed. 
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Figure 6: DeOliveira’s New Proposed Classification 20. 
*“R” indicates right. “L” indicates left. †Based on Bismuth-Corlette classification. ‡Based on the Japanese 
Society of Biliary Surgery classification. §Based on the TNM UICC/AJCC classification. 
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Kaiser’s Prognostic Scoring System  
A recent study 21 proposed a prognostic scoring system including four variables: patients’ years (<62 years 
vs >62), pathological tumor status from TNM stage (pT1 vs pT2-3-4), radical resection (R0 vs R1-2), 
adjuvant chemoradiation (yes vs not performed). Zero or one point is assigned for each variable. From 
personal data set Authors evaluated different variables; variables resulted significant prognostic factors for 
survival at multivariate analysis were included in the proposal scoring system. Authors created a model with 
three groups of patients according to number of variables present; this model allowed to stratify patients and 
to correlate to long-term survival. This is a prognostic scoring system easy to apply, however it has some 
limitations: it is possible to use only after operation because of pathological variables, lymph node 
involvement is not include even in literature has strong prognostic value, pathological tumor extension stage 
was assessed according to TNM UICC/AJCC 6th edition and not to the last 7th edition, definition of Klatskin 
tumor is vague, chemo-radiotherapy in literature has still a questionable prognostic value, it is performed 
after surgery and not always could be performed. This stage system needs an external validation with a 
large cohort of patient.  
 
 
Aim of this study was to evaluate prognostic factors for survival, create a new prognostic model and compare 
it with previous staging and prognostic scoring systems for perihilar cholangiocarcinoma.  
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MATERIAL AND METHODS 
Patients and data collection 
Patients submitted to surgical resection for cholangiocarcinoma in Division of General Surgery of the 
University of Verona Medical School between September 1990 and September 2012 were evaluate for this 
study. Data were collected retrospectively in 2006 and after that prospectively. From database patients with 
perihilar cholangiocarcinoma (PCC) who underwent surgical resection were analyzed. All patients included in 
the study underwent surgical resection with curative intent. Patients who deceased in perioperative period 
(within 30 days after surgery) were excluded from analysis.  
All patients signed informed consent before surgery.  
 
Preoperative evaluation 
The preoperative evaluation included blood chemistry tests with a complete blood count, PT, aPTT, direct 
and total bilirubin, albumin, AST, ALT, ALP, GGT, CEA, CA19.9, alpha-fetoprotein and serology for hepatitis 
viruses (HBV, HCV). The tumor extent was evaluated with ultrasonography, color Doppler ultrasonography 
and CT or MRI. The differential diagnosis between cholangiocarcinoma and gastro-intestinal tumor liver 
metastases was made with tumor histology or by the exclusion of other primary tumors by 
esophagogastroduodenoscopy and colonoscopy. 
In patients with obstructive jaundice, the extent of the tumor was assessed using different diagnostic 
methods during the study period. Between 1990 and 1997, all of the patients underwent percutaneous trans-
hepatic cholangiography (PTC) with the placement of single or multiple biliary drains. Subsequently, non-
invasive diagnostic methods, such as colangio-pancreatography MRI, were primarily used. All patients with 
obstructive jaundice (a serum bilirubin level greater than 3 mg/dL) underwent percutaneous biliary drainage 
to more precisely define the longitudinal extension of the tumor and to reduce the serum bilirubin to less than 
3 mg/dL. A percutaneous trahepatic biliary drainage (PTBD) was preferentially positioned only in the future 
remnant liver. In patients with segmental cholangitis, multiple hepatic drainages of the excluded biliary 
segments were performed 30 . More recently, endoscopic biliary drainage, CT-PET and diagnostic 
laparoscopy was introduced in selected patients.  
 
Surgical technique 
During surgery, intraoperative ultrasonography was routinely used to confirm the preoperative diagnosis, to 
evaluate the relationship between the tumor and blood vessels and to evaluate the presence of intrahepatic 
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metastases. The extent of liver resection was defined according to the Brisbane classification 31 . Common 
bile duct resection was performed in all cases because of macroscopic involvement by the tumor. In cases of 
bile duct resection, frozen sections of the bile duct were made intraoperatively. 
Lymphadenectomy of the regional LN was classified according to the Japanese Society of Biliary Surgery 
(JSBS) classification 29. The LNs of the hepatoduodenal ligament (12 h, 12a, 12p, 12b), the proper hepatic 
artery (8) and the posterior surface of the pancreatic head (13) were harvested. The paraaortic LNs (16) and 
the LNs of other stations were retrieved if they were macroscopically suspected for metastases. The surgical 
LN dissection technique includes the complete dissection of the hilar structures; all fatty tissue of the 
hepatoduodenal ligament was retrieved and sent to pathologist. 
 
Pathological evaluation 
Tumors classification depended on the location of the main tumor and on the presence of histologically 
proven invasion of the main bile ducts. Tumors with involvement of the hepatic hilus structures requiring 
resection of the biliary confluence associated with the liver and caudate lobe resection in some cases were 
defined as peri-hilar cholangiocarcinoma 6, 24, 32. 
The microscopic direct invasion of the bile duct wall, the portal pedicle and neural tissue was verified in all 
surgical specimens; all fatty tissue surrounding the vessels of the hepatoduodenal ligament and from others 
lymph node stations were analyzed. Metastatic LNs were defined as N+. Invasion of the wall of the major 
portal or hepatic vein branches and confirmed by the pathological examination was defined as macroscopic 
vascular invasion. Failed radical resection (R1) was defined as the presence of microscopic disease at 
resection margins of the specimen (bile ducts and liver). 
 
Postoperative course 
Complications were classified according to the Zurich Classification 33. Complications greater than grade 3a 
were classified as major. When more than one complication occurred, the higher grade was reported. 
Mortality, complication grade 5, was considered as peri-operative mortality if it occurred within 30 days of 
surgery and it was one of exclusion criteria. 
 
Postoperative treatment and follow up 
After surgery, the patients were regularly followed up with blood tests, tumor markers (CEA, CA19.9) and 
abdominal CT or MRI every 6 months. In cases of suspected recurrence at radiological exams, PET-CT was 
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performed. Occurrence of disease recurrence, time of recurrence, decease and time of death were recorded.  
 
Tumor stage classification 
All cases were classified according to Bismuth-Corlette classification 16, to Memorial Sloan-Kettering Cancer 
Center (MSKCC) Tumor Staging 18, 7th edition of the TNM UICC/AJCC classification 17, to Japanese Society 
for Biliary Surgery (JSBS) classification 29 and to Kaiser’s prognostic scoring system 21.  
Prognostic scoring systems or nomogram not specific for perihilar cholangiocarcinoma were included in the 
analysis. 
 
Statistical Analysis 
The differences between categorical and continue variables were analyzed with a chi-square, Fisher’s exact, 
t-student and Mann–Whitney U tests as appropriated. Overall survival (OS) was defined as the time interval 
between treatment and death from any cause. Time was censored at the date of last follow-up assessment 
for patients who were still alive. Survival curves were estimated using the Kaplan-Meier method with the Log 
Rank test to verify significance of differences. Variables statistically significant at univariate analysis were 
investigated in the Cox model and by testing (using a likelihood-ratio test) whether the coefficient of the 
interaction term was significantly different from zero. A p-value lower then 0.05 was considered statistically 
significant. These statistical analyses and graphical representation were carried out using the R software for 
statistical computing, v. 2.15.0 (R Development Core Team, 2010), with the following packages: survival, 
Himsc. 
We searched a prognostic clinical model based on multivariate Cox’s models in order to classify patients in 
different classes of increased risk of dead. According to the parameters selected in the multivariate Cox 
model, we designed a prognostic model of OS. The final model identified was then fitted as a mathematical 
function, which resulted the risk to die before or equal to 36 months after surgical resection. To make the 
model more easily accessible in the clinical practice, a nomogram was proposed. For every prognostic factor 
a partial score was computed. The sum of partial scores gives a total points score that permits to predict the 
risk to die before or equal to 36 months. In order to confirm the importance of our model we classified 
patients in low risk (≤50%), medium risk (between 50% and 75%) and high risk (>75%) to die according to 
predictions based on our clinical model. 
The performance of the nomogram was assessed by comparing nomogram-predicted versus observed 
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Kaplan-Meier estimates of survival probability. Bootstraps with 5000 resamples were used for internal 
validation.  
Patients were categorized according to current four staging systems previously described: TNM stage 7th 
edition, MSKCC staging system, JSBS staging system, Kaiser prognostic scoring system.  
The discriminatory ability of each staging system and of our proposed staging system was examined by 
expressing the consequences of the Cox model on the basis of the Akaike Information Criterion (AIC).  
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RESULTS 
 
Clinicopathological Characteristics of Patients 
From September 1990 to September 2012, 207 patients underwent surgery for ICC and PCC. After 
abdominal exploration, 145 patients underwent surgical resection with curative intent. 
Seventy-five patients were classified as PCC. Six patients were excluded from analysis because of 
perioperative mortality; 69 patients were included in the study. 
Clinical characteristics are summarised in table 1. Nineteen patients were female (27.5%) and 50 male 
(72.5). Median age was 66 (range 30-83). Majority of patients were symptomatic (79.7%) at time of diagnosis 
and symptom most frequent was jaundice (76.8%); 33 patients (47.8%) underwent positioning of biliary 
drainage. Preoperative median value of CA 19.9 was 95 U/mL with range between 3.5 U/mL and 6835 U/mL. 
Tumor was classified as Bismut-Corlette type I or type II in 10 cases, type IIIa or IIIb in 17 and 28 cases and 
type IV in 14 cases. Three patients were submitted to preoperative portal vein embolization because of small 
remnant liver volume.  
 
 
 
Table 1: Clinical characteristics.  
 
  Nr. Cases 
69 
Percentage 
100% 
Gender Female 19 27.5 
 Male 50 72.5 
Age  Median; range 66; 30 - 83  
Symptoms Present 55 79.7 
 Absent 14 20.3 
Jaundice Present 53 76.8 
 Absent 16 23.2 
Preoperative biliary drainage Positioned 33 47.8 
 Not positioned 36 52.2 
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Liver status Normal 56 81.2 
 Pathological* 13 18.8 
CEA (ng/dL) Median; range 2.05; 0.2 - 83  
CA 19.9 (U/mL) Median; range 95; 3.5 - 6835  
Preoperative portal vein embolization Performed 3 4.3 
 Not performed 66 95.7 
Bismuth-Corlette type I 4 5.8 
 II 6 8.7 
 IIIa / IIIb 17 / 28 24.6 / 40.6 
 IV 14 20.3 
Neoadiuvant chemotherapy Performed 4 5.8 
 Not performed 65 94.2 
* Liver status pathological: cirrhosis, fibrosis, steatosis. 
 
 
 
 
 
Majority of patients were operated after 2005 (40 after 2005 and 29 before). Surgical variables are 
summarized in table 2. Resection of only common bile duct (CBD) was performed in 10 patients; all these 
cases were performed before 2005. Minor liver resections associated to CBD resection were performed in 2 
patients (only caudate lobe in one case and caudate lobe plus segment 4 in the other); majority of patients 
were submitted to major liver resection. Caudate lobe resection was performed in 56 (81.2%) of patients and 
lymph node dissection in 66 (95.7%) of patients. Resection and reconstruction of hepatic vein or hepatic 
artery due to vascular infiltration by tumor were performed in 13 and 4 cases respectively. Median operation 
time was 547 minutes (range 250-780). Postoperative complications occurred in 30 patients and median 
postoperative length of stay was 19 days with range between 7 and 213 days. 
Postoperative complications occurred in 30 patients (43.5%). Complications equal to or greater than grade 
3a, excluding grade 5, occurred in 6 (8.7%) patients. 
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Table 2: Surgical characteristics. 
 
  Nr. Cases 
69 
Percentage 
100% 
Operation period Before 2005 29 42 
 After 2005 40 58 
Operation type Bile duct resection only 10 14.5 
 Segmentect- / Bisegmentectomy 2 2.8 
 Right hepatectomy 17 24.6 
 Right trisectionectomy 8 11.6 
 Left hepatectomy 27 39.1 
 Left trisectionectomy 5 7.2 
Liver resection side Right side 25 43.9% 
 Left side 32 56.1% 
Liver resection Associated to CBD resection 59 85.5 
 Not performed 10 14.5 
Hepatectomy Minor 2 3.3 
 Major 57 96.6 
Caudate lobe resection Performed 56 81.2 
 Not performed 13 18.2 
Vascular clamping Without clamping 50 72.5 
 Pringle maneuver 14 20.3 
 Selective clamping 5 7.2 
Lymph node dissection Performed 66 95.7 
 Not performed 3 4.3 
Portal vein resection Performed 13 18.8 
 Not performed 56 81.2 
Hepatic artery resection Performed 4 5.8 
 Not performed 65 94.2 
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Operative time (minutes) Median; range 547; 250 - 780  
Postoperative hospital stay (days) Median; range 19; 7-213  
Postoperative complications Occurred 30 43.5 
 Not occurred 39  56.5 
 
 
 
 
Pathological data are reported in table 3. Radical resection was obtained in 52 patients (75.4%). Median 
tumor diameter was of 2.5 cm (range 2-12); tumor grading was G1 and G2 in 16 and 39 cases and G3 and 
G4 in 13 and 1 case, respectively. Satellites tumor nodules were present in 8 cases. Macroscopic vascular 
invasion of major brunch of portal vein or hepatic artery or common portal vein or hepatic artery were present 
in 43 cases (62.3%). Perineural infiltration was present majority of patients (89.9%). Median number of 
harvested lymph node was 7 (range 1-27); lymph nodes were positive in 27 patients (40.9%) and median 
number of positive lymph node was 3 (1-10); Pathological tumor classification according to UICC/AJCC TNM 
7th Edition were stage as I, IIA and IIB in 32 cases (46.4%) and III and IV in 37 (53.6%) of cases. Patients 
were classified according to TNM 7th Edition as stage I and II in 25 cases (36.6%), in stage IIIA or IIIB in 23 
cases (33.3%) and in stage IVA or IVB in 21 cases (30.4%), respectively.  
Median follow up was of 22 months (range 4-107). Median overall survival was 26 months; cumulative 
proportion survival at 3 and 5 years were 44% and 28% respectively. Disease recurrence occurred in 18 
patients; median overall disease free survival was 24 months with disease free survival at 3 and 5 years of 
35% and 21% respectively. 
 
 
Table 3: Pathological characteristics. 
 
  Nr. Cases 
69 
Percentage 
100% 
Curability R0 52 75.4 
 R1 17 24.6 
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Tumor diameter (cm) Median; range 2.5; 2 - 12  
Grading tumor G1 – G2 16 – 39 23.2 – 56.5 
 G3 – G4 13 - 1 18.8 – 1.4 
Satellites nodules Present 8 11.6 
 Absent 61 88.4 
Macroscopic vascular invasion Present 43 62.3 
 Absent 26 37.7 
Microscopic vascular invasion Present 50 72.5 
 Absent 19 27.5 
Perineural infiltration Present  62 89.9 
 Absent 7 10.1 
Glissonian infiltration Present 25 36.2 
 Absent 44 63.8 
Pathological Tumor classification* I 4 5.8 
 IIA – IIB 16 – 12 23.2 – 17.4 
 III 21 30.4 
 IV 16 23.2 
Number lymph node harvested Median; range 7; 1 – 27  
Lymph node status N0 39 59.1 
 N+ 27 40.9 
Number lymph node positive Median; range 3; 1 - 10  
Pathological Node classification* N0 39 59.1 
 N1 19 28.8 
 N2 8 12.1 
TNM Stage* I 4 5.8 
 II 21 30.4 
 IIIA - IIIB 12 - 11 17.4 – 15.9 
 IVA 13 18.8 
 IVB 8 11.6 
* Classification according to UICC/AJCC Cancer Staging System, TNM 7th Edition.  
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Univariate analysis 
Univariate analysis of different clinical variables is reported in Table 4. Only preoperative CA 19.9 and 
operation performed after 2005 resulted as positive prognostic factors for longer survival; median survival 
was 42 months for patients with CA 19.9 lower than 400 U/mL and for patients operated after 2005.  
 
Table 4: Univariate analysis of clinical variables collected. CI: Confidence interval. 
  Median survival 
(95% CI) 
3y survival 5y survival p-value 
Gender Female 45.5 (9-81) 52% 41% 0.30 
 Male 25 (17-33) 41% 22%  
Age  ≤62 years 23 (15-32) 41% 20% 0.65 
 >62 years 26 (9-42) 46% 30%  
Liver status Normal 23 (19-28) 39% 24% 0.17 
 Pathological 42 (5-79) 65% 43%  
Symptoms Present 28 (10-47) 47% 32% 0.27 
 Absent 22 (16-29) 34% 17%  
Jaundice Present 28 (10-47) 47% 32% 0.24 
 Absent 22 (15-29) 35% 17%  
Biliary drainage Positioned 26 (17-35) 44% 37% 0.66 
 Not positioned 34 (12-57) 47% 25%  
CEA (ng/dL) ≤4 42 (22-62) 63% - 0.17 
 >4 13 (0-32) 25% -  
CA 19.9 (U/mL) ≤500 42 (28-56) 64% 33% 0.004 
 >500 15 (7-22) - -  
Bismuth type I-II 21 (14-28) 33% 0% 0.11 
 IIIA-IIIB 36 (15-58) 51% 42%  
 IV 22 (7-37) 32% 16%  
Operation period Before 2005 20 (15-24) 27% 14% 0.02 
 After 2005 42 (36-58) 60% 46%  
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From surgical variables (Table 5) major hepatectomy, caudate lobe resection, portal vein resection and 
reconstruction, and lymph node dissection were positive prognostic factors for longer survival. Patients who 
underwent major hepatectomy associated to common bile duct resection reached longer survival than 
patients submitted to only CBD resection or to minor liver resection with median survival of 40 and 18 
months (p=0.04), respectively. Median survival, when caudate lobe resection was performed, was 36 months 
instead of 15 months (p=0.05). Median survival of patients without lymph node dissection was 7 months and 
no one patient reached 3 years survival. Median survival of patients, in whom resection and reconstruction of 
portal vein was necessary, had a shorter survival with a median survival of 15 months compared to 35 
months for patients without vascular resection (p=0.001). 
 
Table 5: Univariate analysis of surgical variables. CBD: common bile duct. S1: caudate lobe. CI: confidence 
interval. 
  Median survival 
(95% CI) 
3y survival 5y survival p-value 
Liver resection Associated to 
CBD resection 
35 (17-52) 48% 32% 0.07 
 Not performed 18 (17-52) 22% 0%  
Liver resection Right side 29 (7-50) 45% 27% 0.68 
 Left side 35 (17-52) 49% 39%  
Hepatectomy Minor/only CDB 18 (12-24) 27% 0% 0.04 
 Major 40 (17-52) 48% 35%  
S1 resection Performed 36 (17-56) 51% 31% 0.05 
 Not performed 15 (8-22) 16% 0%  
LN dissection Performed 28 (13-44) 46% 29% 0.001 
 Not performed 7 (0-15) 0% 0%  
Vascular resection Performed 15 (3-27) 18% 5% 0.001 
 Not performed 35 (12-57) 48% 31%  
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From pathological variables (Table 6) presence of satellites nodules was related of short term survival, with 
median survival of 6 months (p=0.001) and no one patient live at 5 years. Pathological tumor stage I and II 
combined had a median survival of 42 months compared to 15 months of stage III and IV combined 
(p=0.002). Extension of lymph node dissection results to be a protective prognostic factor: patients with more 
than 10 LNs harvested had a significantly longer median survival (37 months instead of 19 months) 
compared to patients with less than 10 LNs harvested (p=0.002). Lymph node status was a significant 
prognostic factor: patients with positive LN had a shorter survival (15 months instead of 28 months for 
patients without LN metastasis; p=0.04). Number of positive LN resulted to be a prognostic factor: patients 
with more than 3 positive lymph nodes had a shorter survival compared to patient without positive lymph 
nodes or with less than 3 positive lymph nodes, with median survival of 11, 43 and 35 months, respectively 
(p=0.01). Also lymph node ratio could significantly differentiate prognosis of patients (p=0.01); patients with 
LNR inferior to 0.25 had a longer survival than patients with LNR greater than 0.25 and similar to patients 
with LNR equal to 0 (p=0.19). Also pathological node stage (N0, N1, N2) according to TNM UICC/AJCC 7th 
classification was a strong prognostic factor for survival (p<0.001). 
 
Table 6: Univariate analysis of surgical variables. CBD: common bile duct. S1: caudate lobe. CI: confidence 
interval. 
  Median survival 
(95% CI) 
3y 
survival 
5y 
survival 
p-value 
Curability R0 28 (15-42) 45% 34% 0.12 
 R1 21 (10-31) 41% 10%  
Grading tumor G1 – G2 34 (13-57) 47% 33% 0.35 
 G3 – G4 25 (9-40) 35% 23%  
Tumor diameter ≤2 cm  42 (15-68) 52% 36% 0.32 
Satellites nodules Present 6 (0-16) 17% - 0.001 
 Absent 35 (16-53) 48% 30%  
Macroscopic vascular invasion Present 23 (19-28) 38% 34% 0.87 
 Absent 42 (17-66) 54% 24%  
Microscopic vascular invasion Present 35 (20-50) 46% 41% 0.92 
 Absent 42 (10-74) 59% 29%  
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Perineural infiltration Present  26 (12-39) 43% 36% 0.35 
 Absent 22 (7-38) 40% 0%  
Glissonian infiltration Present 36 (19-54) 56% 34% 0.96 
 Absent 26 (1-56) 48% 31%  
Pathological Tumor stage* I-II 42 (31-53) 51% 27% 0.002 
 III-IV 15 (11-26) 16% 11%  
Number LN harvested <10 19 (13-28) 25% 9% 0.002 
 >10 37 (NA) 70% 56%  
Lymph node status N0 28 (19-61) 49% 28% 0.04 
 N+ 15 (11-36) 20% 13%  
Number N+ harvested 0 43 (41-44) 60% 35% 0.01# 
 1-3 35 (20-50) 48% 39%  
 >3 11 (7-15) 0% 0%  
Lymph node ratio 0 43 (41-44) 60% 35% 0.01§ 
 0-0.25 26 (16-35) 41% -  
 >0.25 11 (0-31) 0% 0%  
Pathological Noda stage* N0 43 (41-44) 60% 35% <0.001 
 N1 20 (3-37) 25% -  
 N2 22 (1-19) 22% 0%  
* Tumor and Node classification according to UICC/AJCC Cancer Staging System, TNM 7th Edition.  
# Positive LN harvested: 0 LN+ vs 1-3 LN+ p=0.74; 0 LN+ vs >3 LN+ p<0.001; 1-3 LN+ vs >3 LN+ p=0.004. 
§ Lymph node ratio: LNR equal to 0 compared to LNR between 0 and 0.25 was not significantly different 
(p=0.19). 
 
 
 
Different scoring systems were evaluated. UICC/AJCC TNM stage 7th edition reached significant different 
only between stage II and stage IVB (p=0.03), however globally did not correlate with survival. If combined 
stage I and II compared to stage III and IV, the staging system could reach statistical prognostic value 
(p=0.03). Different stages according to MSKCC were not statistically different in median survival. Also JSBS 
does not correlate with survival but could reach significantly different survival between stage II and IVB 
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(p=0.008). Keiser prognostic scoring system applied to our population was a prognostic value for survival; 
significantly different survival was reached between stage 6 and 8, with median survival of 42 and 11 
months, respectively (p=0.03). Combining group of patients with 6 or 7 points compared to patients with 8 
points statistically difference was reached (median survival of 22 months compare to 8 months; p=0.02). 
 
Table 7: Univariate analysis of different scoring systems. TNM: UICC/AJCC scoring system 7th edition. 
MSKCC: Memorial Sloan-Kettering Cancer Center. JSBS: Japanese Society of Biliary Surgery. CI: 
confidence interval. NA: not applicable. 
 
  Median survival 
(95% CI) 
3y survival 5y survival p-value 
TNM Stage 7th Eds I-II 43 (41-44) 66% 33% 0.03† 
 III-IV 20 (11-28) 25% 20%  
MSKCC Stage 1-2 23 (18-45) 42% 20% 0.49 
 3 22 (11-28) 20% 0%  
JSBS Stage I-II 42 (29-NA) 58% 12% 0.24° 
 III-IV 20 (13-26) 25% 0%  
KEISER prognostic 
scoring system 
6-7 22 (20-43) 37% 22% 0.02# 
 8 8 (3-NA) 13% 0%  
† TNM 7th edition: stage I vs II p=0.49; stage I vs IIIA p=0.67; stage I vs IIIB p=0.89; stage I vs IVA p=0.32; 
stage I vs IVB p=0.19; stage II vs IIIA p=0.37; stage II vs IIIB p=0.83; stage II vs IVA p=0.13; stage II vs IVB 
p=0.03; stage IIIA vs IIIB p=0.36; stage IIIA vs IVA p=0.39, stage IIIA vs IVB p=0.88; stage IIIB vs IVA 
p=0.09; stage IIIB vs IVB p=0.17; stage IVA vs IVB p=0.48. 
° JSBS stage: stage I vs II p=0.25; stage I vs III p=0.45; stage I vs IVA p=0.79; stage I vs IVB p=0.21; stage 
II vs III p=0.16; stage II vs IVA p=0.60; stage II vs IVB p=0.008; stage III vs IVA p=0.37; stage III vs IVB 
p=0.72; stage IVA vs IVB p=0.59. 
# Keiser prognostic scoring system: score 6 vs 7 p= 0.38; score 6 vs 8 p=0.14; score 7 vs 8 p=0.03. 
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Independent Prognostic Factors in the Cohort 
At multivariate analysis (Table 8) number of harvested lymph node (HR 0.89; 95% CI 0.85-0.93) (p<0.001) 
and caudate lobe resection (HR 0.33; 95% CI 0.14-0.79) (p=0.01) were positive prognostic factor for 
survival. Instead, CA 19.9 greater than 500 U/mL (HR 3.38; 95% CI 1.54-7.43) (p=0.002), number of 
harvested positive lymph node (HR 1.20; 95% CI 0.98-1.48) (p=0.05) and portal vein resection and 
reconstruction (HR 7.14; 95% CI 2.75-18.76) (p<0.001) were independent prognostic factors for shorter 
survival.  
 
 
 
 
 
 
 
Table 8: Multivariate survival analysis of different variables related to overall survival in perihilar (PCC) 
cholangiocarcinoma using the Cox proportional hazards model. HR: hazard ratios. CI: confidence interval.   
 
Variables HR 95% CI p value 
CA19.9 (>500 U/mL) 3.38 1.54 – 7.43 0.002 
Number lymph node harvested 0.89 0.85 – 0.93 <0.001 
Number positive lymph node harvested 1.20 0.98 – 1.48 0.05 
Caudate lobe resection (performed) 0.33 0.14 – 0.79 0.01 
Vascular resection and reconstruction (performed) 7.14 2.75 – 18.76 <0.001 
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Prognostic Nomogram for Overall Survival and comparison to others Prognostic Score 
The prognostic nomogram that integrates all significant independent prognostic factors for OS is shown in 
Fig. 7. For each variable’s value of nomogram correspond a partial score and the sum of partial scores 
allows to predict risk of mortality at 3 years after operation. 
 
 
 
Figure 7. Perihilar cholangiocarcinoma survival nomogram. LN: lymph node. N°N+: number positive lymph 
node harvested. S1: caudate lobe. PV: portal vein. 
 
 
 
 
 
According to our nomogram patients were classified in three groups according to probability to die within 3 
years: low risk (<50%), medium risk (between 50% and 75%) and high risk (>75%) group of patients. 
The calibration plot for the probability of survival at 3 year after surgery showed an optimal agreement 
between the prediction by nomogram and our cohort of patients (Figure 8). 
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Figure 8: Calibration curve for predicting patients survival at 3 years after surgical resection. Nomogram-
predicted probability of overall survival is plotted on the x-axis; actual overall survival is plotted on the y-axis. 
 
After that we would compare our predicting model with others staging systems. Survival was evaluated 
stratifying patients according to different staging systems: TNM 7th edition, MSKCC staging system, JSBS 
staging system and Keiser prognostic scoring system (Figure 9). UICC/AJCC TNM 7th edition staging system 
(stage I-II versus stage III-IV) and Keiser score (group points 6-7 compared to group 8) significantly 
differentiate survival. Instead, MSKCC classification and JSBS staging system were not able to significantly 
differentiate prognosis of our cohort of patients. Our proposed prognostic model could significantly 
differentiate survival of three different groups of patients according to risk of decease at 3 years. Survival 
between group of patients with low risk and medium risk and especially between low risk and high risk were 
statistically significant (p=0.04 and p<0.001 respectively) (Figure 10) (Table 9). Our proposed prognostic 
model for perihilar cholangiocarcinoma after surgical resection reached the greater significant value in 
predicting survival comparing to other staging systems evaluated (AIC 286.9) (Table 9); our model could 
stratify patients in three groups and good correlate with survival. 
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Figure 9: Kaplan-Meier survival curves of patients submitted to surgical resection according to different 
prognostic scoring systems. TNM: AICC/UICC TNM staging system 7th edition. MSKCC: Memorial Sloan-
Kattering Cancer Center classification. JSBS: Japanese Society of Biliary Suergery. Kaiser: Kaiser 
prognostic scoring system. 
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Figure 10. Kaplan-Meier survival curves of patients submitted to surgical resection according to our 
proposed prognostic system for perihilar cholangiocarcinoma. Low risk: 3 years mortality risk lower than 
50%. Medium risk: 3 years mortality risk between 50% and 75%. High risk: 3 years mortality risk greater than 
75%. Low vs medium risk: p-value 0.04. Low vs high risk: p-value <0.001. 
 
 
 
 
 
Table 9: Evaluation of different staging systems.  
TNM stage: pathological stage according to AICC/UICC staging system. MSKCC: Memorial Sloan-Kettering 
Cancer Canter classification. Kaiser: prognostic scoring system. JSBS: Japanese Society for bile  
 
Variables H.R. 95% CI P value  AIC 
TNM Stage (I-II vs stage III-IV)  2.60 1.39 – 4.87 0.002 306.1 
MSKCC Classification (1-2 vs 3) 1.32 0.72 – 2.40 0.361 331.0 
JSBS Staging System (I-II vs III-IV) 1.48 0.77 – 2.85 0.24 313.7 
Kaiser Prognostic System (6-7 vs 8) 2.66 1.27 – 5.56 0.02 310.9 
Perihilar Prognostic Classification 
(Low vs Medium Risk) 
(Low vs High Risk) 
 
4.35 
23.71 
 
1.05 – 17-9 
6.84 – 82.1 
 
0.04 
<0.001 
268.9 
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DISCUSSION 
 
Cholangiocarcinoma is the second most frequent primary liver tumor and its incidence is increased in 
Western countries in last 30 years 3. Perihilar cholangiocarcinoma is defined as biliary tumor originating and 
located in the biliary confluence and extending to extrahepatic biliary tree either to intrahepatic parenchyma 7 
. Perihilar cholangiocarcinoma is rarely operable and even when surgical operation is feasible long term 
survival is dismal but surgical resection is the only chance to cure this aggressive disease 34 . Surgical 
management is demanding, however recent aggressive surgical operations could reach good long-term 
survival 34.   
Different clinicopathological factors have been previously evaluated and related to survival: radical resection, 
vascular invasion, tumor size, multifocality, tumor grading, perineural invasion, lymph node metastasis, 
tumor stage and positive resection margins 10, 26, 35-40 . 
In our study we evaluated several clinical and pathological variables of patients submitted to surgical 
resection with radical intent. From univariate analysis CA 19.9 preoperative value greater than 500 U/mL 
was a significant prognostic factor for survival reflecting biological behaviour of tumor. CA 19.9 is a tumor 
marker increased in other gastrointestinal tumors; also in others series of patients with perihilar 
cholangiocarcinoma was related with poor prognosis 41, 42 43 . CA 19.9 is an easily available test laboratory 
that could correlate with poor survival and especially it’s available preoperatively. Patients submitted to 
surgical resection after 2005 had a longer survival; this longer survival, as confirmed from other studies, is 
due to more aggressive surgical treatment 34, 37, 44 . Also from our data, aggressive treatment reach longer 
survival; indeed, major hepatectomy, caudate lobe resection and lymph node dissection were significant 
prognostic factor for longer survival. Lymph node metastasis is a strong prognostic factor and was already 
evaluated in literature 34-36, 45, 46 . Lymph node metastasis is a prognostic factor per se but patients with low 
value lymph node ratio (<0.25) have survival similar to patients without positive lymph node. For this reasons 
we suggest to perform an extensive lymph node dissection to better stratify patients. Patients with more than 
10 lymph node harvested had a significantly longer survival. In literature extension of lymph node dissection 
is still under discussion, however recent studies are giving important additional data about that 35 47 .   
Cancers are classified in different staging systems. Tumor staging system is important to have a 
classification of tumor reflecting prognosis, to guide for therapy and to compare results of different case 
series among various institution and over time. Perihilar cholangiocarcinoma is increasing in last years and 
clinical and surgical approach is evolving in last years; for this reasons, few classifications are available and 
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they are still under discussion and modification. Bismuth-Corlette evaluates clinical and radiological extention 
of tumor along bile ducts and it gives information about operability and extension of surgical resection. This 
classification was evaluated in different studies however it was not associated with prognostic significance 28. 
Also in our study Bismuth classification did not have significant prognostic value for survival. MSKCC 
classification was proposed to evaluate preoperative respectability, however it did not correspond to current 
concepts of respectability anymore. The Authors demonstrated value of classification to predict resectability 
and also to correlate with survival, however different Authors not reached same results in different cohort of 
patients. Similarly, in our study MSKCC classification did not correlated with prognosis. The last edition of 
TNM UICC/AJCC classification included a specifically classification for perihilar cholangiocarcinoma, 
because in previous edition (6th edition) the perihilar tumor was included with extrahepatic bile duct cancer. 
Pathological tumor stage (pT stage) and TNM stage according to 7th edition were evaluated in literature as 
prognostic factor 36. In our study stratifying patients in 4 stages we did not reach significant difference, but 
comparing stage I-II to stage III-IV it correlates to long term survival. Limitation of TNM stage is that it is not 
applicable preoperatively because it is based on pathological report. JSBS staging system is a quite complex 
pathological classification and it has limited application in clinical practice. We classified patients according 
to JSBS, however it could not predict prognosis. The new proposed staging system for perihilar 
cholangiocarcinoma is only a descriptive system and up to now it has not a prognostic function.  
Recently was published a novel prognostic scoring system for Klatskin tumor by group from Essen 21. This is 
the first attempt to create a prognostic scoring system for surgical treatment of perihilar cholangiocarcinoma; 
it includes clinical (age), pathological (surgical margin and tumor stage) and postoperative variables 
(adjuvant chemo-radiotherapy). This is an easy and reproducible system, however it includes questionable 
variables. Radical resection, even in large series, could be obtained only in about 60% of patients 34 and it is 
not a strong prognostic factor for this type of tumor (studio R+) and incomplete resection (R2) has worst 
prognosis than R1 resection. Pathological tumor stage I is quite rare for this type of tumor, also in large 
series 34, 36. Finally, Authors classified tumor with TNM 6th edition instead of more recent one.  
Recently a score system 48 and a nomogram 49 for resected biliary tract cancer were published . In a small 
series of patients including 2 patients with extrahepatic cholangiocarcinoma and 5 patients with Klatskin 
tumor, Authors created a point score with preoperative and postoperative blood level of AST, ALT Bilirubin 
and CA 19.9, symptoms at diagnosis and site of tumor. This is an interesting study, however not specific for 
perihilar cholangiocarcinoma. In addition, patients with PCC often have jaundice at diagnosis and need 
preoperative biliary drainage to reduce postoperative complication 30 ; moreover, jaundice increases CA 19.9 
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blood level 42 . Nomogram proposed by group of van Gulik for patients undergoing resection of extrahepatic 
cholangiocarcinoma, included lymph node status, microscopic residual tumor at resection margin, tumor 
differentiation grade. Tumor location was not inserted in the nomogram because it did not independently 
predicted survival after tumor resection. Nomogram could predict survival better than TNM stage. Even 
location did not predict survival in this study, perihilar and distal cholangiocarcinoma have different type of 
surgical management and different prognosis in literature. In our analysis we did not considered these two 
scoring system and nomogram described, because they are not specific for perihilar cholangiocarcinoma, 
however in future we could investigate also these interesting aspects. 
Nomograms have been developed and shown to be more accurate than conventional staging systems for 
predicting prognosis 50, 51 . Thus, because of limited variables included in pathological staging systems and 
lack of prognostic staging systems, we tried to construct a nomogram including clinical and pathological 
variables for patients submitted to surgical operation for perihilar cholangiocarcinoma. At multivariate 
analysis CA 19.9 serum level, caudate lobe resection, vascular resection and reconstruction, number of 
lymph node harvested and number of positive lymph node, confirmed to be strong prognostic factors. We 
create a nomogram with these five clinical, surgical and pathological variables. Nomogram was able to well 
predict survival and his prediction was internally validated with calibration curve. From our nomogram we 
could create a prognostic model stratifying patients in 3 groups with different risk to deceased within 3 years. 
Applying different staging system to our population TNM staging system and Kaiser’s prognostic scoring 
system were able to predict survival, although our predicting model showed better predictive accuracy for 
survival. Moreover our nomogram includes important clinical, as CA 19.9, and surgical prognostic factors, 
otherwise not considered in other staging system. TNM stage was not included in our prognostic model, 
because lymph node status was a strongest prognostic variable compared to pathological tumor stage. TNM 
stage system has some limitation in the correct classification of perihilar cholangiocarcinoma and in almost 
of studies it is able to correlate to survival only if combining different stages.  
There are several limitations on this study. First, creation of nomogram and prognostic scoring system was 
performed from a small cohort of patients and from a single European institution. External validation with 
more cases should be performed. Second limitation is that also this prognostic scoring system is applicable 
only after surgical operation, even if we included also clinical variable. Relevant clinical and radiological 
prognostic factors should be included in a preoperative prognostic scoring system to predict survival and to 
address best treatment. As for other gastrointestinal tumor, molecular markers are increasing also for 
cholangiocarcinoma and in future should be incorporate in preoperative staging system. Third, our 
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nomogram includes caudate lobe resection and portal vein resection-reconstruction; currently caudate lobe 
has to be resected in every patient with perihilar cholangiocarcinoma submitted to surgical resection, 
therefore it should not be different from patient to another and probably in the future it will be less strong 
prognostic factor. Portal vein resection and reconstruction could be a bad prognostic factor due to 
macroscopic vascular infiltration, however it could not be necessary related with infiltration and moreover 
Neuhaus theorized “en-bloc” resection of liver with portal vein confluence obtaining longer survival even in 
patients without portal vein infiltration 52. Finally, pathological lymph node count after surgical dissection 
should be standardized because it could be dissimilar in different institutions. 
Our nomogram good correlates with survival; it includes prognostic factor related to biological behaviour of 
tumor (CA 19.9, number of positive lymph node) and surgical characteristics necessary to obtain radical 
resection (caudate lobe resection, lymph node harvested and portal vein resection). In the future knowledge 
about specific circulating tumor cells, molecular prognostic factors and new adjuvant chemotherapy has to 
be developed, therefore to incorporate that in a new prognostic scoring system.  
 
 
.
	   38 
CONCLUSION 
 
Perihilar cholangiocarcinoma is an aggressive tumor with bad prognosis and so far surgical resection is the 
only chance to cure. Our nomogram, including CA 19.9, number of lymph node harvested, number of 
positive lymph node, caudate lobe resection and portal vein resection, could well predict prognosis of 
patients after surgical resection and could address adjuvant treatment and follow up. 
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